跳至主要内容
临床试验/CTIS2023-510084-35-00
CTIS2023-510084-35-00招募中1 期

Tocilizumab for Painful Chronic Pancreatitis: A Randomised, Placebo-controlled, Double-blinded, Investigator-initiated Trial (TOPAC trial)

Aalborg University Hospital0 个研究点目标入组 36 人开始时间: 2023年12月22日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Signed informed consent, Probable or definitive diagnosis of CP according to the M-ANNHEIM criteria. This entails a typical clinical history of CP, including recurrent pancreatitis or abdominal pain in combination with the following additional criteria (specific details for definitive (New ID 3) and for probable (New ID 4)), A definitive diagnosis of CP is established by one or more of the following additional criteria: (i) Pancreatic calcification, (ii) Moderate or marked ductal lesions (according to the Cambridge classification), (iii) Exocrine pancreatic insufficiency, defined as pancreatic steatorrhea markedly reduced by enzyme supplementation, and/or (iv) Histological verification of CP., A probable diagnosis of CP is established by one or more of the following additional criteria: (i) Mild ductal alterations (according to the Cambridge classification), (ii) Recurrent or persistent pseudocysts, (iii) Pathological test of pancreatic exocrine function (such as faecal elastase-1 test, secretin test, secretin-pancreozymin test), and/or (iv) Diabetes mellitus, Abdominal pain of presumed pancreatic origin (i.e., upper abdominal pain radiating to the back)., Evidence of ongoing pancreatic inflammatory activity, with an inflammatory pancreatic flare occurring one or more times within the past six months. An inflammatory pancreatic flare is defined as an exacerbation of pancreatic pain in combination with one or more of the following criteria: (i) Plasma amylase levels elevated 2-fold or more of the participant's usual amylase level, (ii) Elevated plasma levels of CRP 2-fold the upper normal level without suspicion of other sources such as infection, and/or (iii) Signs of pancreatic inflammation on cross-sectional imaging, = 18 years of age, The participant must be able to read and understand the informed consent forms, The participant is willing and able to comply with the scheduled visits, treatment plan, and other trial procedures

排除标准

  • End-stage CP indicated by severe pancreatic atrophy defined as segmented pancreas volume <20 ml on the latest available cross-sectional imaging examination (computed tomography or MRI)., Pregnancy, fertile women (<55 years) must provide a urine sample for pregnancy test upon inclusion., Pancreatic duct obstruction by a stricture and/or stone amendable to endoscopic or surgical treatment. Patients with previous pancreatic duct decompression procedures are allowed to participate., Ongoing alcohol or substance abuse. The patient must document abstinence from alcohol and substance abuse for the preceding six months prior to study enrolment. Recreational alcohol consumption within the safety limits recommended by the National Danish Health Authorities (i.e., max. ten units of alcohol per week) is allowed., Active or recurrent infections., Untreated ulcers in the gastrointestinal tract (however, those who have undergone proper treatment and one month has elapsed with no recurrence of symptoms will not be excluded)., Known hypersensitivity to Tocilizumab., Severe liver disease, indicated by ALT with >5 upper normal limit., Thrombocytopenia (platelet count < 50 x 109/L)., Neutropenia (neutrophil count <2 x 109/L).

研究者

相似试验

Tocilizumab for Painful Chronic Pancreatitis... | 临床试验